The burden of cancer in Spain

Badia, Xavier; Tort, M.; Manganelli, Anton-Giulio; Camps, Carlos; Dı́az-Rubio, Eduardo

doi:10.1007/s12094-018-1972-7

Cited by 12 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The COVID-19 impact on the Spanish public health budget during the peak of the pandemic (86 days), considering direct medical costs only, was estimated at over €9.4 billion (12.3% of total public health expenditure) [10]. This is greater than the impact reported for numerous conditions in Spain, such as multiple sclerosis (€1.4 billion) [11], cancer (€4.8 billion) [12], and diabetes (€5.8 billion) [13]. These figures give a picture of how big the cost of the pandemic has been at its peak in Spain.…”

Section: Discussionmentioning

confidence: 99%

Hospitalization budget impact during the COVID-19 pandemic in Spain

et al. 2021

View full text Add to dashboard Cite

Objectives The aim was to determine the direct impact of the COVID-19 pandemic on Spain’s health budget. Methods Budget impact analyses based on retrospective data from patients with suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) admitted to a Spanish hospital between February 26 and May 21, 2020. Direct medical costs from the perspective of the hospital were calculated. We analyzed diagnostic tests, drugs, medical and nursing care, and isolation ward and ICU stays for three cohorts: patients seen in the emergency room only, hospitalized patients who tested positive for SARS-CoV-2, and patients who tested negative. Results The impact on the hospital’s budget for the 3 months was calculated at €15,633,180, 97.4% of which was related to health care and hospitalization. ICU stays accounted for 5.3% of the total costs. The mean cost per patient was €10,744. The main costs were staffing costs (10,131 to 11,357 €/patient for physicians and 10,274 to 11,215 €/patient for nurses). Scenario analysis showed that the range of hospital expenditure was between €14,693,256 and €16,524,924. The median impact of the pandemic on the Spanish health budget in the sensitivity analysis using bootstrapped individual data was €9357 million (interquartile range [IQR], 9071 to 9689) for the conservative scenario (113,588 hospital admissions and 11,664 ICU admissions) and €10,385 million (IQR, 110,030 to 10,758) for the worst-case scenario (including suspected cases). Conclusion The impact of COVID-19 on the Spanish public health budget (12.3% of total public health expenditure) is greater than multiple sclerosis, cancer and diabetes cost.

show abstract

Section: Discussionmentioning

confidence: 99%

Hospitalization budget impact during the COVID-19 pandemic in Spain

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Cancer is one of the diseases with the greatest impact on public health and is the second leading cause of death in Europe [ 1 ]. In Spain, colorectal cancer (CRC) is frequently diagnosed [ 2 ], mostly in people older than 50 years, with an average age of onset between 70 and 71 years [ 3 ] and with a higher incidence in men than in women [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

The economic impact of anastomotic leak after colorectal cancer surgery

et al. 2023

View full text Add to dashboard Cite

Objective To determine the economic impact of the incremental consumption of resources for the diagnosis and treatment of anastomotic leak (AL) in patients after resection with anastomosis for colorectal cancer compared to patients without AL on the Spanish health system. Method This study included a literature review with parameters validated by experts and the development of a cost analysis model to estimate the incremental resource consumption of patients with AL versus those without. The patients were divided into three groups: 1) colon cancer (CC) with resection, anastomosis and AL; 2) rectal cancer (RC) with resection, anastomosis without protective stoma and AL; and 3) RC with resection, anastomosis with protective stoma and AL. Results The average total incremental cost per patient was €38,819 and €32,599 for CC and RC, respectively. The cost of AL diagnosis per patient was €1018 (CC) and €1030 (RC). The cost of AL treatment per patient in Group 1 ranged from €13,753 (type B) to €44,985 (type C + stoma), that in Group 2 ranged from €7348 (type A) to €44,398 (type C + stoma), and that in Group 3 ranged from €6197 (type A) to €34,414 (type C). Hospital stays represented the highest cost for all groups. In RC, protective stoma was found to minimize the economic consequences of AL. Conclusions The appearance of AL generates a considerable increase in the consumption of health resources, mainly due to an increase in hospital stays. The more complex the AL, the higher the cost associated with its treatment. Interest of the study it is the first cost-analysis study of AL after CR surgery based on prospective, observational and multicenter studies, with a clear, accepted and uniform definition of AL and estimated over a period of 30 days.

show abstract

“…Likewise, in Europe, the expenditure on cancer medicines has tripled from €10 billion to €32 billion between 2005 and 2018 ( 5 ). In Spain, the consumption of antineoplastic drugs represented a total cost of €1,717 million in 2015, corresponding to about 36% of direct costs of cancer, 2.6% of public health expenditure, and 0.16% of the Spanish GDP ( 6 ). In addition, the number of active oncology clinical trials is also increasing.…”

Section: Introductionmentioning

confidence: 99%

A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application

et al. 2022

View full text Add to dashboard Cite

BackgroundOncology clinical trials can lead to relevant financial savings in drug acquisition for healthcare providers. Considerable methodological heterogeneity is observed among previous studies estimating these savings.MethodsWe developed a methodology to estimate the economic benefit obtained from the enrollment of patients into clinical trials through the analysis of drug cost avoidance. We designed a decision algorithm to determine if a clinical trial is associated with drug cost avoidance. This algorithm is based on five scenarios according to the availability or not of standard treatment, the presence or absence of a control arm (placebo or active treatment), and the provider of the medication. We considered as reference the cost of the standard treatment that the patient would have received in routine clinical practice. We standardized drug doses and treatment durations according to the literature. Costs were considered from a National Health System perspective. We applied this methodology at a single, research-active University Hospital in 2019. A cost avoidance analysis per trial and patient was carried out on cancer patients.ResultsWe analyzed 140 trials in which 198 patients were recruited. Drug cost avoidance was found in 120 trials (85.7%). The estimated total drug cost avoidance amounted to over €3,200,000. Melanoma and genitourinary tumors were the tumor types associated with the highest cost avoidance. The average drug cost avoidance per patient was €16,245.ConclusionWe describe a standardized method to estimate drug cost avoidance in clinical trials. We have applied it to all ongoing oncology clinical trials in our center. This methodology could be valuable for other centers to analyze the potential saving of clinical trials.

show abstract

The burden of cancer in Spain

Cited by 12 publications

References 10 publications

Hospitalization budget impact during the COVID-19 pandemic in Spain

Hospitalization budget impact during the COVID-19 pandemic in Spain

The economic impact of anastomotic leak after colorectal cancer surgery

A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application

Contact Info

Product

Resources

About